CHADDS FORD, Pa., March 17 Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, Mar. 23, 2010, at 10:15 a.m. EDT. David Holveck, president and chief executive officer of Endo, will review the company's products and development programs.
The presentation will be webcast live and can be accessed from Endo's website at www.endo.com under the investors section.
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, prostate cancer, bladder cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM(®), a topical patch to relieve the pain of postherpetic neuralgia; Percocet(®) and Percodan(®) tablets for the relief of moderate-to-moderately severe pain; FROVA(®) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(® )tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(®) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren(® )Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTAS(®) for the palliative treatment of advanced prostate cancer; SUPPRELIN(®) LA for the treatment of early onset puberty in children; and VALSTAR(TM) for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks. The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.
SOURCE Endo Pharmaceuticals